Dosing and monitoring of low-molecular-weight heparin in high-risk pregnancy: Single-center experience

Pharmacotherapy

Volumn 31, Issue 7, 2011, Pages 678-685

  Shapiro, Nancy L ^a   Kominiarek, Michelle A ^a   Nutescu, Edith A ^a   Chevalier, Aimee B ^a   Hibbard, Judith U ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

Anticoagulation; Antifactor Xa activity; Dosing; Enoxaparin; LMWH; Low molecular weight heparin; Monitoring; Pregnancy

Indexed keywords

BLOOD CLOTTING FACTOR 10A; DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ADULT; ARTICLE; BLEEDING; BODY WEIGHT; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE INCREASE; DRUG MONITORING; FEMALE; FIRST TRIMESTER PREGNANCY; HIGH RISK PREGNANCY; HUMAN; LUNG EMBOLISM; MITRAL VALVE REPLACEMENT; OBSERVATIONAL STUDY; PATIENT MONITORING; RETROSPECTIVE STUDY; SECOND TRIMESTER PREGNANCY; SKIN BRUISING; THIRD TRIMESTER PREGNANCY; THROMBOSIS PREVENTION; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; VENOUS THROMBOEMBOLISM;

ACADEMIC MEDICAL CENTERS; ADULT; ANTICOAGULANTS; BODY WEIGHT; COHORT STUDIES; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; ENOXAPARIN; FACTOR XA; FEMALE; HUMANS; PREGNANCY; PREGNANCY COMPLICATIONS, HEMATOLOGIC; PREGNANCY TRIMESTERS; PREGNANCY, HIGH-RISK; RETROSPECTIVE STUDIES; VENOUS THROMBOEMBOLISM; YOUNG ADULT;

EID: 79959743178     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.31.7.678     Document Type: Article

References (24)

1. Heron M, Hoyert DL, Murphy SL, et al. Deaths: final data for 2006. Nat Vit Stats Rep 2009;57:1-134.
2. Bates SM. Treatment and prophylaxis of venous thromboembolism during pregnancy. Thromb Res 2002;108:97-106. (Pubitemid 36184644)
3. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians evidence-based clinical practice guidelines, 8th ed. Chest 2008;133(6 suppl):S844-86.
4. American College of Obstetricians and Gynecologists. ACOG committee opinion: safety of Lovenox in pregnancy. Obstet Gynecol 2002;100:845-6.
5. American College of Obstetricians and Gynecologists. Practice bulletin no. 113: inherited thrombophilias in pregnancy. Obstet Gynecol 2010;116:212-22.
6. Casele HL, Laifer SA, Woelkers DA, Venkataramanan R. Changes in the pharmacokinetics of the low-molecular-weight heparin enoxaparin sodium during pregnancy. Am J Obstet Gynecol 1999;181:1113-17.
7. Barbour LA, Oja JL, Schultz LK. A prospective trial that demonstrates that dalteparin requirements increase in pregnancy to maintain therapeutic levels of anticoagulation. Am J Obstet Gynecol 2004;191:1024-9. (Pubitemid 39298153)
8. Jacobsen AF, Qvisgstad E, Sandset PM. Low molecular weight heparin (dalteparin) for treatment of venous thromboembolism in pregnancy. Br J Obstet Gynaecol 2002;110:139-44.
9. Bates SM, Greer IA, Hirsh J, Ginsberg JS. Use of antithrombotic agents during pregnancy: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest 2004;126:S627-44.
10. Greer IA. Anticoagulants in pregnancy. J Thromb Thrombolysis 2006;21:57-65. (Pubitemid 43231130)
11. Anticoagulation in Prosthetic Heart Valves in Pregnancy Consensus Report (APPCR) Panel. Anticoagulation with enoxaparin use in patients with prosthetic heart valves and/or pregnancy. Clin Cardiol Consensus Rep 2002;3:1-20.
12. Casele HL. The use of unfractionated heparin and low molecular weight heparins in pregnancy. Clin Obstet Gynecol 2006;49:895-905. (Pubitemid 44691212)
13. Tooher R, Gates S, Dowswell T, Davis LJ. Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period. Cochrane Database Syst Rev 2010;(5): CD001689.
14. Duhl AJ, Paidas MJ, Ural SH, et al, for the Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007;197:457.e1-21.
15. Monagle P Michelson AD, Bovill E, Andrew M. Antithrombotic therapy in children. Chest 2001;119 (suppl 1):S344-70.
16. Lebaudy E, Hulot JS, Amoura Z, et al. Changes in enoxaparin pharmacokinetics during pregnancy and implications for antithrombotic therapeutic strategy. Clin Pharmacol Ther 2008;84:370-7.
17. Fox NS, Laughon SK, Bender SD, Saltzman DH, Rebarber A. Anti-factor Xa plasma levels in pregnant women receiving low molecular weight heparin thromboprophylaxis. Obstet Gynecol 2008;112:884-9.
18. Ní Ainle F, Wong A, Appleby N, et al. Efficacy and safety of once-daily low molecular weight heparin (tinzaparin sodium) in high risk pregnancy. Blood Coagul Fibrinolysis 2008;19: 689-92.
19. Friedrich E, Hameed AB. Fluctuations in anti-factor Xa levels with therapeutic enoxaparin anticoagulation in pregnancy. J Perinatol 2010;30:253-7.
20. Gates S, Brocklehurst P, Ayers S, Bowler U, on behalf of the Thromboprophylaxis in Pregnancy Advisory Group. Thromboprophylaxis and pregnancy: two randomized controlled pilot trials that used low-molecular-weight heparin. Am J Obstet Gynecol 2004;191:1296-303. (Pubitemid 39421588)
21. Kominiarek MA, Angelopoulos SM, Shapiro NL, Studee L, Nutescu EA, Hibbard JU. Low molecular weight heparins in pregnancy: a case-control study. J Perinatol 2007;27:329-34.
22. Gyamfi C, Cohen R, Desancho MT, Gaddipati S. Prophylactic dosing adjustment in pregnancy based upon measurements of anti-factor Xa levels. J Matern Fetal Neonatal Med 2005;18:329-31. (Pubitemid 43062381)
23. Huxtable LM, Tafreshi MJ, Ondreyco SM. A protocol for the use of enoxaparin during pregnancy: results from 85 pregnancies including 13 multiple gestation pregnancies. Clin Appl Thromb Hemost 2005;11:171-81. (Pubitemid 40548000)
24. Rodie VA, Thomson AJ, Stewart FM, Quinn AJ, Walker ID, Greer IA. Low molecular weight heparin for the treatment of venous thromboembolism in pregnancy: a case series. BJOG 2002;109:1020-4. (Pubitemid 35279133)